Protective effect of sulodexide on podocyte injury in adriamycin nephropathy rats

Abstract

This study examined the effect of sulodexide on podocyte injury in rats with adriamycin nephropathy (AN). A total of 36 healthy male SD rats were randomly assigned to three groups: control group, AN group and sulodexide treatment group. Rat models of AN were established by a single tail intravenous injection of adriamycin (6.5 mg/kg) in both AN group and sulodexide treatment group. Sulodexide (10 mg/kg) was administered the rats in the treatment group once daily by garage from the first day of model establishment until the 14th day or the 28th day. Samples of 24-h urine and renal cortex tissues were harvested at day 14, 28 after the model establishment. Excretion of 24-h urinary protein was measured by Coomassie brilliant blue method. The pathological changes in renal tissues were observed by light microscopy and electron microscopy respectively. Heparanase mRNA was detected by RT-PCR. Expressions of desmin, CD2AP and heparanase were determined by immunohistological staining. The results showed that the expressions of heparanase mRNA and protein were increased in the glomeruli of AN rats at day 14 and 28 after the model establishment, which was accompanied by the increased expression of desmin and CD2AP. The mRNA and protein expression of heparanase was decreased in the sulodexide-treated rats as compared with AN rats at day 14 and 28. And, the protein expression of desmin and CD2AP was reduced as with heparanase in the sulodexide- treated rats. Proteinuria and podocyte foot process effacement were alleviated in the AN rats after sulodexide treatment. There was a positive correlation between the expression of heparanase and the expression of desmin and CD2AP (as well as 24-h urinary protein excretion). It was concluded that increased heparanase is involved in podocyte injury. Sulodexide can maintain and restore podocyte morphology by inhibiting the expression of heparanase in AN.

Keywords

sulodexide / podocyte / heparanase / adriamycin nephropathy

References

[1] ShanklandS.J.. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int, 2006, 69(12): 2131-2147

[2] PatrakkaJ., TryggvasonK.. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol, 2009, 5(8): 463-468

[3] WijnhovenT.J., LensenJ.F., RopsA.L., et al.. Anti-proteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther, 2007, 9(4): 364-377

[4] CoccheriS., ScondottoG., AgnelliH.. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol, 2002, 13(6): 1615-1625

[5] LewisE.J., XuX.. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care, 2008, 31(2): 202-207

[6] VilayurE., HarrisD.C.. Emerging therapies for chronic kidney disease: what is their role?. Nat Rev Nephrol, 2009, 5(7): 375-383

[7] GheorgheG., AdalbertS., MariusR.. The effects of the therapy with natural glycosaminoglycans (sulodexide) on proteinuria in different types of glomerulorphritis. Facta Universitatis Series: Medicine and Biology, 2001, 8(1): 26-30

[8] SmithR.J., AlexanderJ., BarlowP.N., et al.. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol, 2007, 18(9): 2447-2456

[9] XingY., DingJ., FanQ., et al.. Diversities of podocyte molecular changes induced by different antiproteinuria drugs. Exp Biol Med, 2006, 231(5): 585-593

[10] DanielsB., LinhardtR.J., ZhangF., et al.. In vivo antithrombotic synergy of oral heparin and arginine: endothelial thromboresistance without changes in coagulation parameters. Thromb Haemost, 2006, 95(5): 865-872

[11] CeolM., NerlichA., BaggioB., Anglani, et al.. Increased glomerular alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest, 1996, 74(2): 484-495

[12] CiszewiczM., PolubinskaA., AntoniewiczA., et al.. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res, 2009, 153(3): 118-123

[13] CeolM., GambaroG., SauerU., et al.. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol, 2000, 11(12): 2324-2336

[14] AsanumaK., Yanagida-AsanumaE., TakagiM.. The role of podocytes in proteinuria. Nephrology, 2007, 12(3): 15-20

[15] DeegensJ.K., DijkmanH.B., BormG.F., et al.. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int, 2008, 74(12): 1568-1576

[16] ZouJ., YaoitaE., WatanabeY.. Upregulation of nestin, vimentin, and desmin in rat podocytes in response to injury. Virchows Arch, 2006, 448(4): 485-492

[17] ZhengC.X., ChenZ.H., ZengC.H., et al.. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int, 2008, 74(5): 596-612

[18] ChuangP.Y., HeJ.C.. Signaling in regulation of podocyte phenotypes. Nephron Physiol, 2009, 111(2): 9-15

[19] KimJ.M., WuH., GreenG., et al.. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science, 2003, 300(5623): 1298-1300

[20] HuberT.B., HartlebenB., KimJ., et al.. Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling. Mol Cell Biol, 2003, 23(14): 4917-4928

[21] ZhangC., JiangH.J., ChangY., et al.. Downregulation of CD2-associated protein impaired the physiological functions of podocytes. Cell Biol Int, 2009, 33(6): 632-639

[22] LevidiotisV., FreemanC., TikellisC., et al.. Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol, 2004, 15(1): 68-78

[23] LevidiotisV., KanellisJ., IerinoF.L., et al.. Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int, 2001, 60(4): 1287-1296

[24] van den HovenM.J., RopsA.L., BakkerM.A.. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int, 2006, 70(12): 2100-2108

[25] van den HovenM.J., RopsA.L., VlodavskyI.. Heparanase in glomerular diseases. Kidney Int, 2007, 72(5): 543-548